Zobrazeno 1 - 10
of 34
pro vyhledávání: '"M Benmebarek"'
Autor:
S Stock, M Benmebarek, A Kluever, D Darowski, C Jost, K Stubenrauch, J Benz, A Freimoser-Grundschober, E Moessner, P Umana, M Subklewe, S Endres, C Klein, S Kobold
Publikováno v:
Poster Presentations.
Autor:
M Benmebarek, F Märkl, J Keyl, B Cadilha, M Geiger, C Karches, H Obeck, M Schwerdtfeger, D Briukhovetska, J Jobst, PJ Müller, M Seifert, R Grünmeier, M Thomas, C Marr, M Levesque, M Heppt, S Endres, C Klein, S Kobold
Publikováno v:
Oral Presentations.
Autor:
A Gottschlich, M Thomas, R Grünmeier, S Lesch, L Rohrbacher, V Igl, D Briukhovetska, M Benmebarek, S Dede, K Müller, T Xu, D Dhoqina, Ö Umut, F Märkl, S Robinson, A Sendelhofert, H Schulz, B Vick, BL Cadilha, R Brabenec, N Röder, F Rataj, M Nüesch, J Wellbrock, F Modemann, W Fiedler, C Kellner, T Herold, D Paquet, I Jeremias, L von Baumgarten, S Endres, M Subklewe, C Marr, S Kobold
Publikováno v:
Poster Presentations.
Autor:
Maria Rescigno, Abbass Darwich, Hannah Obeck, Claudio Sustmann, Alexandre Taleb, Giuseppe Curigliano, Giovanna Masci, Lapo Morelli, Sebastian Kobold, M. Benmebarek, Alessia Melacarne, Domenico Supino, Alessandra Silvestri, Agnese Losurdo, Giuseppe Penna, Bruno L. Cadilha, Juliette Mouriès
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for the Immunotherapy of Cancer
Journal for the Immunotherapy of Cancer
BackgroundNatural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unident
Autor:
M Benmebarek, F Märkl, J Keyl, B Loureiro Cadilha, M Geiger, C Karches, S Endres, C Klein, S Kobold, A Klüver, M Schwerdtfeger
Publikováno v:
Poster Presentations.
Autor:
A Öner, Bruno L. Cadilha, C. Karches, Stefan Endres, Martina Geiger, M. Benmebarek, Sebastian Kobold, F Märkl, Christian Klein, Melanie Schwerdtfeger, Vincenzo Desiderio
Publikováno v:
Poster Presentations.
Background Chimeric antigen receptor therapy – although very efficacious in B cell malignancies – is facing many challenges which limit its success in solid tumors, e.g. on-target off-tumor toxicities, antigen heterogeneity, lack of T cell migrat
Autor:
Abbass Darwich, Saskia Schmitt, Bettina Brauchle, S Stoiber, Christian Augsberger, Stefan Endres, S Lesch, Sebastian Kobold, Rataj, Christian Klein, B Loureiro Cadilha, Nadja C. Fenn, Marion Subklewe, M Benmebarek, Monika Herrmann, M Schwerdtfeger, Karl-Peter Hopfner, A Gottschlich
Publikováno v:
Poster Presentations.
Background Targeted immunotherapies have shown limited success in the context of acute myeloid leukemia (AML). The mutational landscape, heterogeneity attributed to this malignancy and toxicities associated with the targeting of myeloid lineage antig
Autor:
M Seifert, M Benmebarek, B Cadilha, J Jobst, J Dörr, T Lorenzini, D Dhoqina, J Zhang, U Schindler, S Endres, S Kobold
Publikováno v:
Poster Presentations.
Background Despite remarkable response rates mediated by anti-CD19 chimeric antigen receptor (CAR) T cells in selected B cell malignancies, CAR T cell therapy still lacks efficacy in the vast majority of tumors. A substantial limiting factor of CAR T
Autor:
Monika Herrmann, Nadja C. Fenn, Stefanie Lesch, Christian Klein, Adrian Gottschlich, S Stoiber, Sebastian Kobold, Bruno L. Cadilha, Christian Augsberger, Melanie Schwerdtfeger, Marion Subklewe, Bettina Brauchle, Saskia Schmitt, Stefan Endres, Lisa Rohrbacher, Felicitas Rataj, Abbass Darwich, M. Benmebarek, A Öner, Matthias Seifert, Karl-Peter Hopfner
Publikováno v:
Leukemia
Leukemia 35, 2243–2257 (2021)
Leukemia 35, 2243–2257 (2021)
Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia (AML) has in principle be
Autor:
Marion Subklewe, Sebastian Kobold, Vincenzo Desiderio, M. Benmebarek, Melanie Schwerdtfeger, Stefan Endres
Publikováno v:
Current Hematological Malignancy Reports
Current Hematologic Malignancy Reports
Curr. Hematol. Malig. Rep. 16, 218-233 (2021)
Current Hematologic Malignancy Reports
Curr. Hematol. Malig. Rep. 16, 218-233 (2021)
Purpose of Review Both chimeric antigen receptor (CAR) T cells and T cell–engaging antibodies (BiAb) have been approved for the treatment of hematological malignancies. However, despite targeting the same antigen, they represent very different clas